Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study
| Autor: | Babak Afrough, Mar Cabeza-Cabrerizo, Ulrike Arnold, Jonathan H.J. Baum, Lamine Koivogui, Christopher H. Logue, Luam Ghebreghiorghis, Nicole Hetzelt, Katja Nitzsche, Rahel Lemma Yenamaberhan, Cèline Gurry, Daouda Sissoko, Lauren A. Cowley, Ralf Krumkamp, Martin Rudolf, Carlos M. Castro, Kilian Stoecker, Roman Wölfel, Beate Becker-Ziaja, Sophie Duraffour, Inês Vitoriano, Isabel García-Dorival, Erna Fleischmann, Natasha Y. Rickett, Antonino Di Caro, Marc Mertens, Joseph Akoi Bore, Sarah Meisel, Theresa Enkirch, Sékou Ditinn Cissé, Liana E. Kafetzopoulou, Anna Jaeger, Martin Gabriel, Abigail Kosgei, Fara Raymond Koundouno, Lisa L. Carter, Boubacar Diallo, N’Faly Magassouba, Jürgen May, Tobias Holm, Johanna Repits, Katrin Singethan, Julia Hinzmann, Denis Malvy, Elisa Pallasch, Xavier Anglaret, Stephanie Wurr, Patrick Drury, Antonio Mazzarelli, Eva Lorenz, Sakoba Keita, Claire Levy Marchal, Osvaldo Miranda, Alseny-Modet Camara, Romy Kerber, Géraldine Colin, Sylvain Juchet, Jacques Seraphin Kolié, Stephan Günther, Miles W. Carroll, Abdoul Habib Beavogui, Sabrina Bockholt, Pierre Formenty, Janine Michel, Alvaro Camino, Eeva Kuisma, Giuseppe Ippolito, Livia Victoria Patrono, Andreas Sachse, Jan-Peter Böttcher, Amadou Bah, Elsa Gayle Zekeng, Jasmine Portmann |
|---|---|
| Přispěvatelé: | Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Compassionate Use Trials
Male 0301 basic medicine viruses Kaplan-Meier Estimate Disease medicine.disease_cause epidemic 0302 clinical medicine CHEMISTRY Immunology and Allergy 030212 general & internal medicine Child Univariate analysis Middle Aged Viral Load Ebolavirus ddc 3. Good health Infectious Diseases Child Preschool Pyrazines Viruses Female mobile laboratory Life Sciences & Biomedicine Adult medicine.medical_specialty Adolescent Immunology Ebola virus disease Favipiravir DIAGNOSIS Antiviral Agents Microbiology Major Articles and Brief Reports Young Adult 03 medical and health sciences SIERRA-LEONE Internal medicine medicine Humans In patient ddc:610 Retrospective Studies Cycle threshold Science & Technology Ebola virus business.industry Retrospective cohort study Hemorrhagic Fever Ebola Amides Filovirus VIRAL LOAD 030104 developmental biology Blood chemistry [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie Guinea 610 Medizin und Gesundheit business |
| Zdroj: | JOURNAL OF INFECTIOUS DISEASES Journal of Infectious Diseases Journal of Infectious Diseases, Oxford University Press (OUP), 2019, 220 (2), pp.195-202. ⟨10.1093/infdis/jiz078⟩ The Journal of Infectious Diseases |
| ISSN: | 0022-1899 1537-6613 |
| Popis: | In 2015, favipiravir was administered on a compassionate-use basis to patients with Ebola virus disease in Guinea. This study reveals a trend toward improved survival in favipiravir-treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time. Background In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. The cycle threshold (Ct) of an Ebola virus–specific reverse transcription–polymerase chain reaction assay and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to patients with EVD on a compassionate-use basis. Methods To reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome. Results The case-fatality rate in favipiravir-treated patients was lower than in untreated patients (42.5% [31 of 73] vs 57.8% [52 of 90]; P = .053 by univariate analysis). In multivariate regression analysis, a higher Ct and a younger age were associated with survival (P < .001), while favipiravir treatment showed no statistically significant effect (P = .11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (P = .015). The study also showed characteristic changes in blood chemistry findings in patients who died, compared with survivors. Conclusions Consistent with the JIKI trial, this retrospective study revealed a trend toward improved survival in favipiravir- treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|